Francais | English | Espanõl

Influenza

From Wikipedia, the free encyclopedia

(Redirected from Flu)
Jump to: navigation, search
Editing of this article by unregistered or newly registered users is currently disabled.
Such users may discuss changes, request unprotection, or create an account.
Influenza
Classifications and external resources
TEM of negatively stained influenza virons, magnified approximately 70,000 times.
ICD-10 J10., J11.
ICD-9 487
DiseasesDB 6791
MedlinePlus 000080
eMedicine med/1170  ped/3006

Influenza, commonly known as the flu, is an infectious disease of birds and mammals caused by an RNA virus of the family Orthomyxoviridae (the influenza viruses). In people, common symptoms are fever, sore throat, muscle pains, severe headache, coughing, and weakness and fatigue.<ref name=Merck>Merck Manual Home Edition. Influenza: Viral Infections.</ref> In more serious cases, influenza causes pneumonia, which can be fatal particularly in young children and the elderly. Sometimes confused with the common cold, influenza is a much more severe disease and caused by a different type of virus.<ref name=Eccles>Eccles R (2005). "Understanding the symptoms of the common cold and influenza.". Lancet Infect Dis 5 (11): 718-25. PMID 16253889.</ref> Similarly, the unrelated gastroenteritis is sometimes called "stomach flu" or "24-hour flu".

Typically, influenza is transmitted from infected mammals through the air by coughs or sneezes, creating aerosols containing the virus, and from infected birds through their droppings. Influenza can also be transmitted by saliva, nasal secretions, feces and blood. Infections occur through contact with these bodily fluids or with contaminated surfaces. Flu viruses can remain infectious for over 30 days at 0°C (32°F), about one week at human body temperature, and indefinitely at very cold temperatures (such as lakes in northeast Siberia). They can be inactivated easily by disinfectants and detergents.<ref>Suarez D, Spackman E, Senne D, Bulaga L, Welsch A, Froberg K (2003). "The effect of various disinfectants on detection of avian influenza virus by real time RT-PCR.". Avian Dis 47 (3 Suppl): 1091-5. PMID 14575118.</ref><ref> CIDRAP Avian Influenza (Bird Flu): Implications for Human Disease # Physical characteristics of influenza A viruses</ref><ref> nzherald article Flu viruses 'can live for decades' on ice published November 30, 2006[</ref>

Flu spreads around the world in seasonal epidemics, killing millions of people in pandemic years and hundreds of thousands in non-pandemic years. Three influenza pandemics occurred in the 20th century—each following a major genetic change in the virus—and killed tens of millions of people. Often, these pandemics result from the spread of a flu virus between animal species. Since it first killed humans in Asia in the 1990s a deadly avian strain of H5N1 has posed the greatest influenza pandemic threat. However, this virus has not yet mutated to spread easily between people.<ref>Avian influenza (" bird flu"). WHO (February 2006). Retrieved on 2006-10-20. - Fact sheet</ref>

Vaccinations against influenza are most common in high-risk humans in industrialised countries<ref name=WHOvaccines>WHO position paper : influenza vaccines WHO weekly Epidemiological Record 19 August 2005, vol. 80, 33 (pp 277-288)</ref> and farmed poultry.<ref>Villegas P (1998). "Viral diseases of the respiratory system.". Poult Sci 77 (8): 1143-5. PMID 9706079.</ref> The most common human vaccine is the trivalent flu vaccine that contains purified and inactivated material from three viral strains. Typically this vaccine includes material from two influenza A virus subtypes and one influenza B virus strain.<ref>Horwood F, Macfarlane J. "Pneumococcal and influenza vaccination: current situation and future prospects.". Thorax 57 Suppl 2: II24-II30. PMID 12364707.</ref> A vaccine formulated for one year may be ineffective in the following year, since the influenza virus changes every year and different strains become dominant. Antiviral drugs can be used to treat influenza, with neuraminidase inhibitors being particularly effective.

Flu

Contents

Etymology

The term influenza has its origins in fifteenth-century Italy, where the cause of the disease was ascribed to unfavourable astrological influences. Evolution in medical thought led to its modification to influenza di freddo, meaning "influence of the cold". The word "influenza" was first attested in English in 1743 when it was borrowed during an outbreak of the disease in Europe.<ref name=Harper>Harper D. Influenza. etymonline.com - Online etymology dictionary.</ref> Archaic terms for influenza include epidemic catarrh, grippe, (sometimes spelt "grip" or "gripe"), sweating sickness and Spanish fever (particularly for the 1918 pandemic strain).<ref>Smith P. Online dictionary of archaic medical terms. Accessed 23 Oct 06 Archaic Medical Terms.</ref>

History

Further information: Influenza pandemic, Spanish flu
Negatively stained flu viruses. These were the causative agents of Hong Kong Flu. (Magnified approximately 70,000 times.)

The symptoms of human influenza were clearly described by Hippocrates roughly 2400 years ago.<ref>Martin P, Martin-Granel E (Jun 2006). "2,500-year evolution of the term epidemic". Emerg Infect Dis 12 (6). PMID 16707055.</ref><ref>Hippocrates. Of the Epidemics (written 400 BCE and translated by Francis Adams). Retrieved on 2006-10-18.</ref> Since then, the virus has caused numerous pandemics. Historical data on influenza are difficult to interpret, as the symptoms can be similar to those of other diseases, such as diphtheria, pneumonic plague, typhoid fever, dengue or typhus. The first convincing record of an influenza pandemic was of an outbreak in 1580, which began in Asia and spread to Europe via Africa. In Rome over 8,000 people were killed and several Spanish cities were almost wiped out.<ref name=Potter>Potter CW (Oct 2006). "A History of Influenza". J Appl Microbiol. 91 (4): 572-579. PMID 11576290.</ref> Pandemics continued sporadically throughout the 17th and 18th centuries, with the pandemic of 1830-1833 being particularly widespread; it infected approximately a quarter of the people exposed.<ref name=Potter/>

The most famous and lethal outbreak was the so-called Spanish flu pandemic (type A influenza, H1N1 subtype), which lasted from 1918 to 1919. Older estimates say it killed 40-50 million people<ref name=Patterson1>Patterson KD, Pyle GF. (Spring 1991). "The geography and mortality of the 1918 influenza pandemic.". Bull Hist Med. 65 (1): 4-21. PMID 2021692.</ref> while current estimates say 50 million to 100 million people worldwide were killed.<ref name=Knobler>Chapter 1: The Story of Influenza”, Knobler S, Mack A, Mahmoud A, Lemon S (Editors): The Threat of Pandemic Influenza: Are We Ready? Workshop Summary (2005). Washington DC: The National Academies Press, p60-61.</ref> This pandemic has been described as "the greatest medical holocaust in history" and may have killed as many people as the black death.<ref name=Potter/> This huge death toll was caused by an extremely high infection rate of up to 50%, and the extreme severity of the symptoms.<ref name=Patterson1/> Indeed, symptoms in 1918 were so unusual that initially influenza was misdiagnosed as dengue, cholera, or typhoid. One observer wrote, "One of the most striking of the complications was hemorrhage from mucous membranes, especially from the nose, stomach, and intestine. Bleeding from the ears and petechial hemorrhages in the skin also occurred."<ref name=Knobler/> The majority of deaths were from bacterial pneumonia, a secondary infection caused by influenza, but the virus also killed people directly, causing massive hemorrhages and edema in the lung.<ref name=Taubenberger>Taubenberger J, Reid A, Janczewski T, Fanning T (Dec 29 2001). "Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus.". Philos Trans R Soc Lond B Biol Sci 356 (1416): 1829-39. PMID 11779381.</ref>

The Spanish flu pandemic was truly global, spreading even to the Arctic and remote Pacific islands. The unusually severe disease killed between 2 and 20 % of those infected, as opposed to the more usual flu epidemic mortality rate of 0.1 %.<ref name=Taubenberger/><ref name=Knobler/> Another unusual feature of this pandemic was that it mostly killed young adults, with 99% of pandemic influenza deaths occurring in people under 65 and more than half in young adults 20 to 40 years old.<ref>Simonsen L, Clarke M, Schonberger L, Arden N, Cox N, Fukuda K (Jul 1998). "Pandemic versus epidemic influenza mortality: a pattern of changing age distribution.". J Infect Dis 178 (1): 53-60. PMID 9652423.</ref> This is unusual since influenza is normally most deadly to the very young (under age 2) and the very old (over age 70). The total mortality of the 1918-1919 pandemic is not known, but it is estimated that 2.5 % to 5 % of the world's population was killed. As many as 25 million may have been killed in the first 25 weeks; in contrast, HIV/AIDS has killed 25 million in its first 25 years.<ref name=Knobler/>

Later flu pandemics were not so devastating. They included the 1957 Asian Flu (type A, H2N2 strain) and the 1968 Hong Kong Flu (type A, H3N2 strain), but even these smaller outbreaks killed millions of people. In contrast to 1918 Spanish flu, in later pandemics antibiotics were available to control secondary infections, and this may have helped reduce mortality.<ref name=Taubenberger/>

Known flu pandemics <ref name=Hilleman>Hilleman M (Aug 19 2002). "Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control.". Vaccine 20 (25-26): 3068-87. PMID 12163258.</ref>
Name of pandemic Date Deaths Subtype involved
Asiatic (Russian) Flu 1889-90 1 million possibly H2N2
Spanish Flu 1918-20 40 million H1N1
Asian Flu 1957-58 1 to 1.5 million H2N2
Hong Kong Flu 1968-69 0.75 to 1 million H3N2

The etiological cause of influenza, the Orthomyxoviridae family of viruses, was first discovered in pigs by Richard Schope in 1931.<ref>Shimizu K. (Oct 1997). "History of influenza epidemics and discovery of influenza virus". Nippon Rinsho. 55 (10): 2505-201. PMID 9360364.</ref> This discovery was shortly followed by the isolation of the virus from humans by a group headed by Patrick Laidlaw at the Medical Research Council of the United Kingdom in 1933.<ref>Smith W, Andrewes CH, Laidlaw PP. (1933). "A virus obtained from influenza patients.". Lancet. 2 pages = 66-68.</ref> However, it was not until Wendell Stanley first crystallised tobacco mosaic virus in 1935 that the non-cellular nature of viruses was appreciated.

The first significant step towards preventing influenza was the discovery by Thomas Francis, Jr. in 1944 of a live vaccine for influenza. This built on work by Frank Macfarlane Burnet, who showed that the virus lost virulence when it was cultured in fertilised hen's eggs.<ref>Sir Frank Macfarlane Burnet: Biography The Nobel Foundation. Accessed 22 Oct 06</ref> Application of this observation by Francis allowed his group of researchers at the University of Michigan to develop the first flu vaccine, with support from the U.S. army.<ref>Kendall H (2006). "Vaccine Innovation: Lessons from World War II.". Journal of Public Health Policy 27 (1): 38-57.</ref> The U.S. army was deeply involved in this research due to its experience of influenza in World War I, when thousands of troops were killed by the virus in a matter of months.<ref name=Knobler/>

Although there were scares in New Jersey in 1976 (with the Swine Flu), world-wide in 1977 (with the Russian Flu), and in Hong Kong and other Asian countries in 1997 (with H5N1 avian influenza), there have been no major pandemics since the 1968 Hong Kong Flu. Immunity to previous pandemic influenza strains and vaccination may have limited the spread of the virus, and may have helped prevent further pandemics.<ref name=Hilleman/>

Microbiology

Types of influenza virus

The influenza virus is an RNA virus of the family Orthomyxoviridae, which comprises the influenzaviruses, Isavirus and Thogotovirus. There are three types of influenza virus: Influenzavirus A, Influenzavirus B or Influenzavirus C. Influenza A and C infect multiple species, while influenza B almost exclusively infects humans.<ref name=hay>Hay A, Gregory V, Douglas A, Lin Y (Dec 29 2001). "The evolution of human influenza viruses." (PDF). Philos Trans R Soc Lond B Biol Sci 356 (1416): 1861-70. PMID 11779385.</ref>

The type A viruses are the most virulent human pathogens among the three influenza types and causes the most severe disease. The Influenza A virus can be subdivided into different serotypes based on the antibody response to these viruses.<ref name=hay/> The serotypes that have been confirmed in humans, ordered by the number of known human pandemic deaths, are:

Influenza B virus is almost exclusively a human pathogen, and is less common than influenza A. The only other animal known to be susceptible to influenza B infection is the seal.<ref>Osterhaus A, Rimmelzwaan G, Martina B, Bestebroer T, Fouchier R (2000). "Influenza B virus in seals.". Science 288 (5468): 1051-3. PMID 10807575.</ref> This type of influenza mutates at a rate 2-3 times lower than type A<ref>Nobusawa E, Sato K (Apr 2006). "Comparison of the mutation rates of human influenza A and B viruses.". J Virol 80 (7): 3675-8. PMID 16537638.</ref> and consequently is less genetically diverse, with only one influenza B serotype.<ref name=hay/> As a result of this lack of antigenic diversity, a degree of immunity to influenza B is usually acquired at an early age. However, influenza B mutates enough that lasting immunity is not possible.<ref name=webster>Webster R, Bean W, Gorman O, Chambers T, Kawaoka Y (1992). "Evolution and ecology of influenza A viruses.". Microbiol Rev 56 (1): 152-79. PMID 1579108.</ref> This reduced rate of antigenic change, combined with its limited host range (inhibiting cross species antigenic shift), ensures that pandemics of influenza B do not occur.<ref name=Zambon>Zambon M (Nov 1999). "Epidemiology and pathogenesis of influenza.". J Antimicrob Chemother 44 Suppl B: 3-9. PMID 10877456.</ref>

The influenza C virus infects humans and pigs, and can cause severe illness and local epidemics.<ref>Matsuzaki Y, Sugawara K, Mizuta K, Tsuchiya E, Muraki Y, Hongo S, Suzuki H, Nakamura K (2002). "Antigenic and genetic characterization of influenza C viruses which caused two outbreaks in Yamagata City, Japan, in 1996 and 1998.". J Clin Microbiol 40 (2): 422-9. PMID 11825952.</ref> However, influenza C is less common than the other types and usually seems to cause mild disease in children.<ref>Matsuzaki Y, Katsushima N, Nagai Y, Shoji M, Itagaki T, Sakamoto M, Kitaoka S, Mizuta K, Nishimura H (May 1 2006). "Clinical features of influenza C virus infection in children.". J Infect Dis 193 (9): 1229-35. PMID 16586359.</ref><ref>Katagiri S, Ohizumi A, Homma M (Jul 1983). "An outbreak of type C influenza in a children's home.". J Infect Dis 148 (1): 51-6. PMID 6309999.</ref>

Structure and properties

The following applies for Influenza A viruses, although other strains are very similar in structure<ref> International Committee on Taxonomy of Viruses descriptions of: Orthomyxoviridae Influenzavirus B Influenzavirus C</ref>:

The influenza A virus particle or virion is 80-120 nm in diameter and usually roughly spherical, although filamentous forms can occur.<ref>International Committee on Taxonomy of Viruses. The Universal Virus Database, version 4: Influenza A.</ref> Unusually for a virus, the influenza A genome is not a single piece of nucleic acid; instead, it contains eight pieces of segmented negative-sense RNA (13.5 kilobases total), which encode 11 proteins (HA, NA, NP, M1, M2, NS1, NEP, PA, PB1, PB1-F2, PB2).<ref name=Ghedin>Ghedin E, Sengamalay N, Shumway M, Zaborsky J, Feldblyum T, Subbu V, Spiro D, Sitz J, Koo H, Bolotov P, Dernovoy D, Tatusova T, Bao Y, St George K, Taylor J, Lipman D, Fraser C, Taubenberger J, Salzberg S (Oct 20 2005). "Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution.". Nature 437 (7062): 1162-6. PMID 16208317.</ref> The best-characterised of these viral proteins are hemagglutinin and neuraminidase, two large glycoproteins found on the outside of the viral particles. Neuraminidase is an enzyme involved in the release of progeny virus from infected cells, by cleaving sugars that bind the mature viral particles. By contrast, hemagglutinin is a lectin that mediates binding of the virus to target cells and entry of the viral genome into the target cell.<ref>Suzuki Y (2005). "Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses.". Biol Pharm Bull 28 (3): 399-408. PMID 15744059.</ref> The hemagglutinin (HA or H) and neuraminidase (NA or N) proteins are targets for antiviral drugs.<ref>Wilson J, von Itzstein M (Jul 2003). "Recent strategies in the search for new anti-influenza therapies.". Curr Drug Targets 4 (5): 389-408. PMID 12816348.</ref> These proteins are also recognised by antibodies, i.e. they are antigens.<ref name=Hilleman/> The responses of antibodies to these proteins are used to classify the different serotypes of influenza A viruses, hence the H and N in H5N1.

Infection and replication

Influenza viruses bind through hemagglutinin onto sialic acid sugars on the surfaces of epithelial cells; typically in the nose, throat and lungs of mammals and intestines of birds (Stage 1 in infection figure).<ref name=Wagner>Wagner R, Matrosovich M, Klenk H (May-Jun 2002). "Functional balance between haemagglutinin and neuraminidase in influenza virus infections.". Rev Med Virol 12 (3): 159-66. PMID 11987141.</ref> The cell imports the virus by endocytosis. In the acidic endosome, part of the haemagglutinin protein fuses the viral envelope with the vacuole's membrane, releasing the viral RNA (vRNA) molecules, accessory proteins and RNA-dependent RNA transcriptase into the cytoplasm (Stage 2).<ref>Lakadamyali M, Rust M, Babcock H, Zhuang X (Aug 5 2003). "Visualizing infection of individual influenza viruses.". Proc Natl Acad Sci U S A 100 (16): 9280-5. PMID 12883000.</ref> These proteins and vRNA form a complex that is transported into the cell nucleus, where the RNA-dependent RNA transcriptase begins transcribing complementary positive-sense vRNA (Steps 3a and b).<ref>Cros J, Palese P (Sep 2003). "Trafficking of viral genomic RNA into and out of the nucleus: influenza, Thogoto and Borna disease viruses.". Virus Res 95 (1-2): 3-12. PMID 12921991.</ref> The vRNA is either exported into the cytoplasm and translated (step 4), or remains in the nucleus. Newly-synthesised viral proteins are either secreted through the Golgi apparatus onto the cell surface (in the case of neuraminidase and hemagglutinin, step 5b) or transported back into the nucleus to bind vRNA and form new viral genome particles (step 5a). Other viral proteins have multiple actions in the host cell, including degrading cellular mRNA and using the released nucleotides for vRNA synthesis and also inhibiting translation of host-cell mRNAs.<ref>Kash J, Goodman A, Korth M, Katze M (Jul 2006). "Hijacking of the host-cell response and translational control during influenza virus infection.". Virus Res 119 (1): 111-20. PMID 16630668.</ref>

Negative-sense vRNAs that form the genomes of future viruses, RNA-dependent RNA transcriptase, and other viral proteins are assembled into a virion. Hemagglutinin and neuraminidase molecules cluster into a bulge in the cell membrane. The vRNA and viral core proteins leave the nucleus and enter this membrane protrusion (step 6). The mature virus buds off from the cell in a sphere of host phospholipid membrane, acquiring hemagglutinin and neuraminidase with this membrane coat (step 7).<ref>Nayak D, Hui E, Barman S (Dec 2004). "Assembly and budding of influenza virus.". Virus Res 106 (2): 147-65. PMID 15567494.</ref> As before, the viruses adhere to the cell through hemagglutinin; the mature viruses detach once their neuraminidase has cleaved sialic acid residues from the host cell.<ref name=Wagner/> After the release of new influenza virus, the host cell dies.

Because of the absence of RNA proofreading enzymes, the RNA-dependent RNA transcriptase makes a single nucleotide insertion error roughly every 10 thousand nucleotides, which is the approximate length of the influenza vRNA. Hence, nearly every newly-manufactured influenza virus is a mutant.<ref>Drake J (May 1 1993). "Rates of spontaneous mutation among RNA viruses.". Proc Natl Acad Sci U S A 90 (9): 4171-5. PMID 8387212.</ref> The separation of the genome into eight separate segments of vRNA allows mixing or reassortment of vRNAs if more than one viral line has infected a single cell. The resulting rapid change in viral genetics produces antigenic shifts and allow the virus to infect new host species and quickly overcome protective immunity.<ref name=Hilleman/> This is important in the emergence of pandemics, as discussed in the Epidemiology section.

Symptoms

In humans, influenza's effects are much more severe than those of the common cold, and last longer. Recovery takes about one to two weeks. Influenza can be deadly, especially for the weak, old or chronically ill.<ref name=Hilleman/> According to the on-line version of the Merck Manual of Diagnosis and Therapy:

"Symptoms start 24 to 48 hours after infection and can begin suddenly. Chills or a chilly sensation are often the first indication of influenza. Fever is common during the first few days, and the temperature may rise to 102 to 103 °F (approximately 38 to 39 °C). Many people feel sufficiently ill to remain in bed for days; they have aches and pains throughout the body, most pronounced in the back and legs."<ref name=Merck />

The virus attacks the respiratory tract, is transmitted from person to person by saliva droplets expelled by coughing or sneezing, and can cause the following symptoms:

It can be difficult to distinguish between the common cold and influenza in the early stages of these infections.<ref name=Eccles/> Since anti-viral drugs are most effective in treating influenza if given early (see treatment section, below), it can be important to identify cases early. Of the symptoms listed above, a combination of cough, fever and nasal congestion is good evidence that the infection is influenza.<ref>Monto A, Gravenstein S, Elliott M, Colopy M, Schweinle J (2000). "Clinical signs and symptoms predicting influenza infection.". Arch Intern Med 160 (21): 3243-7. PMID 11088084.</ref>

Most people who get influenza will recover in one to two weeks, but others will develop life-threatening complications (such as pneumonia). According to the World Health Organization: "Every winter, tens of millions of people get the flu. Most are home, sick and miserable, for about a week. Some—mostly the elderly—die. We know the world-wide death toll exceeds a few hundred thousand people a year, but even in developed countries the numbers are uncertain, because medical authorities don't usually verify who actually died of influenza and who died of a flu-like illness."<ref>Peter M. Sandman and Jody Lanard "Bird Flu: Communicating the Risk" 2005 Perspectives in Health Magazine Vol. 10 issue 2.</ref> Even healthy people can be affected, and serious problems from influenza can happen at any age. People over 50 years old, very young children and people of any age with chronic medical conditions, are more likely to get complications from influenza: such as pneumonia, bronchitis, sinus, and ear infections.<ref name=CDCkeyfacts> Key Facts about Influenza (Flu) Vaccine CDC publication. Published October 17, 2006. Accessed 18 Oct 2006.</ref>

The flu can worsen chronic health problems. People with emphysema, chronic bronchitis or asthma may experience shortness of breath while they have the flu, and influenza may cause worsening of coronary heart disease or congestive heart failure.<ref>Angelo SJ, Marshall PS, Chrissoheris MP, Chaves AM. "Clinical characteristics associated with poor outcome in patients acutely infected with Influenza A." Conn Med. 2004 Apr;68(4):199-205. PMID 15095826</ref> Smoking is another risk factor associated with more serious disease and increased mortality from influenza.<ref>Murin S, Bilello K (2005). "Respiratory tract infections: another reason not to smoke.". Cleve Clin J Med 72 (10): 916-20. PMID 16231688.</ref>

Common symptoms of the flu such as fever, headaches, and fatigue, come from the huge amounts of proinflammatory cytokines and chemokines (such as interferon or tumor necrosis factor) produced from influenza-infected cells.<ref name=Eccles/><ref>Schmitz N, Kurrer M, Bachmann M, Kopf M (2005). "Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection.". J Virol 79 (10): 6441-8. PMID 15858027.</ref> In contrast to the rhinovirus that causes the common cold, influenza does cause tissue damage, so symptoms are not entirely due to the inflammatory response.<ref>Winther B, Gwaltney J, Mygind N, Hendley J. "Viral-induced rhinitis.". Am J Rhinol 12 (1): 17-20. PMID 9513654.</ref>

Epidemiology

Seasonal variations

Further information: Flu season

Influenza reaches peak prevalence in winter, and because the Northern and Southern Hemisphere have winter at different times of the year, there are actually two flu seasons each year. This is why the World Health Organization (assisted by the National Influenza Centers) makes recommendations for two different vaccine formulations every year; one for the Northern, and one for the Southern Hemisphere.<ref name=WHOrecommendation>Recommended composition of influenza virus vaccines for use in the 2006–2007 influenza season WHO report 2006-02-14. Accessed 19 October 2006.</ref>

It remains unclear why outbreaks of the flu occur seasonally rather than uniformly throughout the year. One possible explanation is that, because people are indoors more often during the winter, they are in close contact more often, and this promotes transmission from person to person. Another is that cold temperatures lead to drier air, which may dehydrate mucus, preventing the body from effectively expelling virus particles. The virus may also survive longer on exposed surfaces (doorknobs, countertops, etc.) in colder temperatures. Increased travel and visitation due to the Northern Hemisphere winter holiday season may also play a role.<ref> Weather and the Flu Season NPR Day to Day, December 17 2003. Accessed, 19 October 2006</ref> However, seasonal changes in infection rates are also seen in tropical regions and these peaks of infection are seen mainly during the rainy season.<ref> Shek LP, Lee BW. "Epidemiology and seasonality of respiratory tract virus infections in the tropics." Paediatr Respir Rev. 2003 Jun;4(2):105-11. PMID 12758047</ref> Seasonal changes in contact rates from school-terms, which are a major factor in other childhood diseases such as measles and pertussis, may also play a role in flu. A combination of these small seasonal effects may be amplified by "dynamical resonance" with the endogenous disease cycles.<ref>Dushoff J, Plotkin JB, Levin SA, Earn DJ. "Dynamical resonance can account for seasonality of influenza epidemics." Proc Natl Acad Sci U S A. 30 November2004;101(48):16915-6. PMID 15557003</ref> H5N1 exhibits seasonality in both humans and birds.<ref name=WHOH5N1data/>

An alternative hypothesis to explain seasonality in influenza infections is an effect of vitamin D levels on immunity to the virus. <ref>Cannell J, Vieth R, Umhau J, Holick M, Grant W, Madronich S, Garland C, Giovannucci E (2006). "Epidemic influenza and vitamin D.". Epidemiol Infect 134 (6): 1129-40. PMID 16959053.</ref> This idea was first proposed by R. Edgar Hope-Simpson in 1965.<ref>HOPE-SIMPSON R. "The nature of herpes zoster: a long-term study and a new hypothesis.". Proc R Soc Med 58: 9-20. PMID 14267505.</ref> He proposed that the cause of influenza epidemics during winter may be connected to seasonal fluctuations of vitamin D, which is produced in the skin under the influence of solar (or artificial) UV radiation. This could explain why influenza occurs mostly in winter and during the tropical rainy season, when people stay indoors, away from the sun and their vitamin D levels fall. Furthermore, some studies have suggested that administering cod-liver oil, which contains large amounts of vitamin D, can reduce the incidence of respiratory tract infections.<ref>Linday L, Shindledecker R, Tapia-Mendoza J, Dolitsky J (2004). "Effect of daily cod liver oil and a multivitamin-mineral supplement with selenium on upper respiratory tract pediatric visits by young, inner-city, Latino children: randomized pediatric sites.". Ann Otol Rhinol Laryngol 113 (11): 891-901. PMID 15562899.</ref>

Epidemic and pandemic spread

Further information: Flu pandemic

As influenza is caused by a variety of species and strains of viruses, in any given year some strains can die out while others create epidemics while yet another strain can cause a pandemic. Typically, in a year's normal two flu seasons (one per hemisphere) there are between three and five million cases of severe illness and up to 500,000 deaths worldwide, which by some definitions is a yearly influenza epidemic.<ref> Influenza WHO Fact sheet N°211 Revised March 2003. Accessed 22 October 2006</ref> A recent study by the United States Centers for Disease Control and Prevention (CDC) estimated an average of 36,000 deaths each year from influenza-related complications in America.<ref>Thompson W, Shay D, Weintraub E, Brammer L, Cox N, Anderson L, Fukuda K (2003). "Mortality associated with influenza and respiratory syncytial virus in the United States.". JAMA 289 (2): 179-86. PMID 12517228.</ref> Every ten to twenty years a pandemic occurs, which infects a large proportion of the world's population, and can kill tens of millions of people (see history section).

New influenza viruses are constantly being produced by mutation or by reassortment.<ref name=hay/> Mutations can cause small changes in the hemagglutinin and neuraminidase antigens on the surface of the virus. This is called antigenic drift, which creates an increasing variety of strains over time until one of the variants eventually achieves higher fitness, becomes dominant, and rapidly sweeps through the human population often causing an epidemic.<ref> (2006) "Long intervals of stasis punctuated by bursts of positive selection in the seasonal evolution of influenza A virus.". Biol Direct 1 (1): 34. PMID 17067369.</ref> In contrast, when influenza viruses re-assort, they may acquire new antigens - for example by reassortment between avian strains and human strains. This is called antigenic shift. If a human influenza virus is produced with entirely novel antigens, everybody will be susceptible and the novel influenza will spread uncontrollably, causing a pandemic.<ref>Parrish C, Kawaoka Y. "The origins of new pandemic viruses: the acquisition of new host ranges by canine parvovirus and influenza A viruses.". Annu Rev Microbiol 59: 553-86. PMID 16153179.</ref>

Prevention and treatment

Vaccination and hygiene

Further information: Flu vaccine

Vaccination against influenza with a flu vaccine is strongly recommended for high-risk groups, such as children and the elderly. These vaccines can be produced in several ways; the most common method is to grow the virus in fertilised hen eggs. After purification, the virus is inactivated (for example, by treatment with detergent) to produce an inactivated-virus vaccine. Alternatively, the virus can be grown in eggs until it loses virulence and the avirulent virus given as a live vaccine.<ref name=Hilleman/> The effectiveness of these flu vaccines is variable. Due to the high mutation rate of the virus, a particular flu vaccine usually confers protection for no more than a few years. Every year, the World Health Organization predicts which strains of the virus are most likely to be circulating in the next year, allowing pharmaceutical companies to develop vaccines that will provide the best immunity against these strains.<ref name=WHOrecommendation/> Vaccines have also been developed to protect poultry from avian influenza. These vaccines can be effective against multiple strains and are used either as part of a preventative strategy, or combined with culling in attempts to eradicate outbreaks.<ref>Capua I, Alexander D (2006). "The challenge of avian influenza to the veterinary community.". Avian Pathol 35 (3): 189-205. PMID 16753610.</ref>

It is possible to get vaccinated and still get influenza. The vaccine is reformulated each season for a few specific flu strains, but cannot possibly include all the strains actively infecting people in the world for that season. It takes about six months for the manufacturers to formulate and produce the millions of doses required to deal with the seasonal epidemics; occasionally, a new or overlooked strain becomes prominent during that time and infects people although they have been vaccinated (as by the H3N2 Fujian flu in the 2003-2004 flu season).<ref>Holmes E, Ghedin E, Miller N, Taylor J, Bao Y, St George K, Grenfell B, Salzberg S, Fraser C, Lipman D, Taubenberger J (2005). "Whole-genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses.". PLoS Biol 3 (9): e300. PMID 16026181.</ref> It is also possible to get infected just before vaccination and get sick with the very strain that the vaccine is supposed to prevent, as the vaccine takes about two weeks to become effective.<ref name=CDCkeyfacts/>

Vaccination is most important in vulnerable populations, such as children or the elderly. The 2006-2007 season is the first in which the CDC has recommended that children younger than 59 months receive the annual flu vaccine.<ref name=cdcreport> Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP) CDC report (MMWR 2006 Jul 28;55(RR10):1-42) Accessed 19 Oct 06.</ref> Vaccines can cause the immune system to react as if the body were actually being infected, and general infection symptoms (many cold and flu symptoms are just general infection symptoms) can appear, though these symptoms are usually not as severe or long-lasting as influenza. The most dangerous side-effect is a severe allergic reaction to either the virus material itself, or residues from the hen eggs used to grow the influenza; however, these reactions are extremely rare.<ref> Questions & Answers: Flu Shot CDC publication Updated Jul 24, 2006. Accessed 19 Oct 06.</ref>

Good personal health and hygiene habits are reasonably effective in avoiding and minimizing influenza. Since influenza spreads through aerosols and contact with contaminated surfaces, it is important to persuade people to cover their mouths while sneezing and to wash their hands regularly.<ref name=cdcreport/>

Treatment

Further information: Flu treatment

People with the flu are advised to get plenty of rest, drink a lot of liquids, avoid using alcohol and tobacco and, if necessary, take medications such as acetaminophen (paracetamol) to relieve the fever and muscle aches associated with the flu. Children and teenagers with flu symptoms (particularly fever) should avoid taking aspirin during an influenza infection (especially influenza type B) because doing so can lead to Reye syndrome, a rare but potentially fatal disease of the liver.<ref>Glasgow J, Middleton B (2001). "Reye syndrome--insights on causation and prognosis.". Arch Dis Child 85 (5): 351-3. PMID 11668090.</ref>

Since influenza is caused by a virus, antibiotics have no effect on the infection; unless prescribed for secondary infections such as bacterial pneumonia, they may lead to resistant bacteria. Antiviral medication is sometimes effective, but viruses can develop resistance to the standard antiviral drugs. The antiviral drugs amantadine and rimantadine are designed to block a viral ion channel and prevent the virus from infecting cells. These drugs are sometimes effective against influenza A if given early in the infection, but are always ineffective against influenza B.<ref name=Stephenson>Stephenson I, Nicholson K (1999). "Chemotherapeutic control of influenza.". J Antimicrob Chemother 44 (1): 6-10. PMID 10459804.</ref> Measured resistance to amantadine and rimantadine in American isolates of H3N2 has increased to 91% in 2005.<ref> (2006) "High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005-06 influenza season.". MMWR Morb Mortal Wkly Rep 55 (2): 44-6. PMID 16424859.</ref> Antiviral drugs such as oseltamivir (trade name Tamiflu) and zanamivir (trade name Relenza) are neuraminidase inhibitors that are designed to halt the spread of the virus in the body.<ref name=Neuraminidase_inhibitors> Moscona A (2005). "Neuraminidase inhibitors for influenza.". N Engl J Med 353 (13): 1363-73. PMID 16192481.</ref> These drugs are often effective against both influenza A and B.<ref name=Stephenson/> Resistance has not yet been a problem with neuraminidase inhibitors. Resistant viruses have been identified but, unlike the situation with amantadine, in which the resistant viruses are fully virulent and able to transmit, that does not appear to be the case with neuraminidase.<ref> A Monto (2006). The Fight Against Seasonal Influenza.</ref><ref name=Neuraminidase_inhibitors/> Different strains of influenza virus have differing degrees of resistance against these antivirals and it is impossible to predict what degree of resistance a future pandemic strain might have.<ref> Robert G. Webster (2006). "H5N1 Influenza — Continuing Evolution and Spread". N Engl J Med 355 (21): 2174-2177. PMID 16192481.</ref>

Research

Further information: Flu research

Research on influenza includes studies on molecular virology, how the virus produces disease (pathogenesis), host immune responses, viral genomics, and how the virus spreads (epidemiology). These studies help in developing influenza countermeasures; for example, a better understanding of the body's immune response aids in vaccine development, and a detailed picture of how influenza invades cells aids in the development of antiviral drugs. One important basic research program is the Influenza Genome Sequencing Project, which is creating a library of influenza sequences; this library should help to clarify which factors make one strain more lethal than another, which genes most affect immunogenicity, and how the virus evolves over time.<ref> Influenza A Virus Genome Project at The Institute of Genomic Research. Accessed 19 Oct 06</ref>

Research into new vaccines is particularly important: as current vaccines are slow and expensive to produce and must be reformulated every year. The sequencing of the influenza genome and recombinant DNA technology may accelerate the generation of new vaccine strains by allowing scientists to substitute new antigens into a previously-developed vaccine strain.<ref>Subbarao K, Katz J. "Influenza vaccines generated by reverse genetics.". Curr Top Microbiol Immunol 283: 313-42. PMID 15298174.</ref> New technologies are also being developed to grow virus in cell culture; which promises higher yields, less cost, better quality and surge capacity.<ref>Bardiya N, Bae J (2005). "Influenza vaccines: recent advances in production technologies.". Appl Microbiol Biotechnol 67 (3): 299-305. PMID 15660212.</ref> The US government has purchased from Sanofi Pasteur and Chiron Corporation several million doses of vaccine meant to be used in case of an influenza pandemic of H5N1 avian influenza and is conducting clinical trials with these vaccines.<ref> New York Times article ""Doubt Cast on Stockpile of a Vaccine for Bird Flu"" by Denise Grady. Published: March 30, 2006. Accessed 19 Oct 06</ref>

Infection in other animals

H5N1
WHO pandemic phases
  1. Low risk
  2. New virus
  3. Self limiting
  4. Person to person
  5. Epidemic exists
  6. Pandemic exists
Further information: Influenzavirus A, H5N1 and Transmission and infection of H5N1

Influenza infects many animal species and transfer of viral strains between species can occur. Birds are thought to be the main animal reservoirs of influenza viruses.<ref>Gorman O, Bean W, Kawaoka Y, Webster R (1990). "Evolution of the nucleoprotein gene of influenza A virus.". J Virol 64 (4): 1487-97. PMID 2319644.</ref> Sixteen forms of hemagglutinin and 9 forms of neuraminidase have been identified. All known subtypes (HxNy) are found in birds but many subtypes are endemic in humans, dogs, horses, and pigs; populations of camels, ferrets, cats, seals, mink, and whales also show evidence of prior infection or exposure to influenza.<ref name=webster/> Variants of flu virus are sometimes named according to the species the strain is endemic in or adapted to. The main variants named using this convention are: Bird flu, Human Flu, Swine Flu, Horse Flu and Dog Flu. (Cat flu generally refers to Feline viral rhinotracheitis or Feline calicivirus and not infection from an influenza virus.) In pigs, horses and dogs influenza symptoms are similar to humans, with cough, fever and loss of appetite.<ref name=webster/> The frequency of animal diseases are not as well-studied as human infection, but an outbreak of influenza in harbour seals caused approximately 500 seal deaths off the New England coast in 1979-1980.<ref>Hinshaw V, Bean W, Webster R, Rehg J, Fiorelli P, Early G, Geraci J, St Aubin D (1984). "Are seals frequently infected with avian influenza viruses?". J Virol 51 (3): 863-5. PMID 6471169.</ref> On the other hand, outbreaks in pigs are common and do not cause severe mortality.<ref name=webster/>

Flu symptoms in birds are variable and can be unspecific.<ref>Elbers A, Koch G, Bouma A (2005). "Performance of clinical signs in poultry for the detection of outbreaks during the avian influenza A (H7N7) epidemic in The Netherlands in 2003.". Avian Pathol 34 (3): 181-7. PMID 16191700.</ref> The symptoms following infection with low-pathogenicity avian influenza may be as mild as ruffled feathers, a small reduction in egg production or weight loss combined with minor respiratory disease.<ref>Capua I, Mutinelli F. "Low pathogenicity (LPAI) and highly pathogenic (HPAI) avian influenza in turkeys and chicken." In: Capua I, Mutinelli F. (eds.), A Colour Atlas and Text on Avian Influenza, Papi Editore, Bologna, 2001, pp. 13-20</ref> Since these mild symptoms can make diagnosis in the field difficult, tracking the spread of avian influenza requires laboratory testing of samples from infected birds. Some strains such as Asian H9N2 are highly virulent to poultry, and may cause more extreme symptoms and significant mortality.<ref>Bano S, Naeem K, Malik S (2003). "Evaluation of pathogenic potential of avian influenza virus serotype H9N2 in chickens.". Avian Dis 47 (3 Suppl): 817-22. PMID 14575070.</ref> In its most highly pathogenic form, influenza in chickens and turkeys produces a sudden appearance of severe symptoms and almost 100 % mortality within two days.<ref>Swayne D, Suarez D (2000). "Highly pathogenic avian influenza.". Rev Sci Tech 19 (2): 463-82. PMID 10935274.</ref> As the virus spreads rapidly in the crowded conditions seen in the intensive farming of chickens and turkeys, these outbreaks can cause large economic losses to poultry farmers.

An avian-adapted, highly pathogenic strain of H5N1 (called HPAI A(H5N1), for "highly pathogenic avian influenza virus of type A of subtype H5N1") causes H5N1 flu, commonly known as "avian influenza" or simply "bird flu", and is endemic in many bird populations, especially in Southeast Asia. This Asian lineage strain of HPAI A(H5N1) is spreading globally. It is epizootic (an epidemic in non-humans) and panzootic (a disease affecting animals of many species, especially over a wide area) killing tens of millions of birds and spurring the culling of hundreds of millions of other birds in an attempt to control its spread. Most references in the media to "bird flu" and most references to H5N1 are about this specific strain.<ref>Li K, Guan Y, Wang J, Smith G, Xu K, Duan L, Rahardjo A, Puthavathana P, Buranathai C, Nguyen T, Estoepangestie A, Chaisingh A, Auewarakul P, Long H, Hanh N, Webby R, Poon L, Chen H, Shortridge K, Yuen K, Webster R, Peiris J (2004). "Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia.". Nature 430 (6996): 209-13. PMID 15241415.</ref><ref>Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, Rahardjo AP, Puthavathana P, Buranathai C, Nguyen TD, Estoepangestie AT, Chaisingh A, Auewarakul P, Long HT, Hanh NT, Webby RJ, Poon LL, Chen H, Shortridge KF, Yuen KY, Webster RG, Peiris JS. "The Threat of Pandemic Influenza: Are We Ready?" Workshop Summary The National Academies Press (2005) "Today's Pandemic Threat: Genesis of a Highly Pathogenic and Potentially Pandemic H5N1 Influenza Virus in Eastern Asia", pages 116-130</ref>

At present, HPAI A(H5N1) is an avian disease and there is no evidence suggesting efficient human-to-human transmission of HPAI A(H5N1). In almost all cases, those infected have had extensive physical contact with infected birds.<ref>Liu J (2006). "Avian influenza--a pandemic waiting to happen?". J Microbiol Immunol Infect 39 (1): 4-10. PMID 16440117.</ref> In the future, H5N1 may mutate or reassort into a strain capable of efficient human-to-human transmission. Due to its high lethality and virulence, its endemic presence, its large and increasing biological host reservoir, the H5N1 virus is the world's pandemic threat in the 2006-7 flu season, and billions of dollars are being raised and spent researching H5N1 and preparing for a potential influenza pandemic.<ref name=Rosenthal> Rosenthal, E. and Bradsher, K. Is Business Ready for a Flu Pandemic? The New York Times 16-03-2006 Accessed 17-04-2006</ref>

Economic impact

Further information: Social impact of H5N1

Influenza produces direct costs due to lost productivity and associated medical treatment, as well as indirect costs of preventative measures. In the United States influenza is responsible for a total cost of over $10 billion per year, while it has been estimated that a future pandemic could cause hundreds of billions of dollars in direct and indirect costs.<ref>Statement from President George Bush on Influenza Accessed 26 Oct 2006</ref> However, the economic impact of past pandemics have not been intensively studied and some authors have suggested that the Spanish influenza actually had a positive long-term effect on per-capita income growth, despite a large reduction in the working population and severe short-term depressive effects.<ref>Brainerd, E. and M. Siegler (2003), “The Economic Effects of the 1918 Influenza Epidemic”, CEPR Discussion Paper, no. 3791.</ref> Other studies have attempted to predict the costs of a pandemic as serious as the 1918 Spanish flu on the U.S. economy, where 30 percent of all workers became ill, and 2.5 percent were killed. A 30 percent sickness rate and a three-week length of illness would decrease gross domestic product by 5 percent. Additional costs would come from medical treatment of 18 million to 45 million people, and total economic costs would be approximately $700 billion.<ref>Poland G (2006). "Vaccines against avian influenza--a race against time.". N Engl J Med 354 (13): 1411-3. PMID 16571885.</ref>

Preventative costs are also high. Governments worldwide have spent billions of U.S. dollars preparing and planning for a potential H5N1 avian influenza pandemic: with costs associated with purchasing drugs and vaccines as well as developing disaster drills and strategies for improved border controls.<ref name=Rosenthal/> On November 1 2005 President George Bush unveiled the National Strategy To Safeguard Against The Danger of Pandemic Influenza<ref>National Strategy for Pandemic Influenza Whitehouse.gov Accessed 26 Oct 2006.</ref> backed by a request to Congress for 7.1 billion U.S. dollars to begin implementing the plan.<ref>Bush Outlines $7 Billion Pandemic Flu Preparedness Plan State.gov. Accessed 26 Oct 2006</ref> Internationally, on January 18 2006 donor nations pledged two billion U.S. dollars to combat bird flu at the two day International Pledging Conference on Avian and Human Influenza held in China.<ref>Donor Nations Pledge $1.85 Billion to Combat Bird Flu Newswire Accessed 26 Oct 2006.</ref>

Up to 2006, over ten billion dollars have been spent and over two hundred million birds have been killed to try to contain H5N1 avian influenza.<ref>Avian Influenza and its Global Implications US AID. Accessed 26 Oct 2006.</ref> However, as these efforts have been largely ineffective at controlling the spread of the virus, other approaches are being tried: for example, the Vietnamese government in 2005 adopted a combination of mass poultry vaccination, disinfecting, culling, information campaigns and bans on live poultry in cities.<ref> Reuters Vietnam to unveil advanced plan to fight bird flu published on April 28, 2006. Accessed 26 Oct 2006</ref> As a result of such measures, the cost of poultry farming has increased, while the cost to consumers has gone down due to demand for poultry falling below supply. This has resulted in devastating losses for many farmers. Poor poultry farmers can not afford mandated measures keeping their bird livestock from contact with wild birds (and other measures) thus risking losing their livelihood altogether. Multinational poultry farming is increasingly becoming unprofitable as H5N1 avian influenza becomes endemic in wild birds worldwide.<ref>Poultry sector suffers despite absence of bird flu UN Office for the Coordination of Humanitarian Affairs. Accessed 26 Oct 2006</ref> Financial ruin for poor poultry farmers, that can be as severe as threatening starvation, has caused some to commit suicide and many others to stop cooperating with efforts to deal with this virus; further increasing the human toll, the spread of the disease and the chances of a pandemic mutation.<ref>Nine poultry farmers commit suicide in flu-hit India Reuters. Published on April 12, 2006. Accessed 26 Oct 2006.</ref><ref>In the Nile Delta, Bird Flu Preys on Ignorance and Poverty New York Times. Published on April 13, 2006. Accessed 26 Oct 2006.</ref>

See also

Wikimedia Commons has media related to:
Information concerning flu research can be found at

References and notes

<references/>

Further reading

General

History

Microbiology

Pathogenesis

Epidemiology

Treatment and prevention

  • CDC 2005. Centers for Disease Control. Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005; 54 (RR08): 1-40. - Full text.
  • Arnold S. Monto Vaccines and Antiviral Drugs in Pandemic Preparedness Emerging Infectious Diseases Special Issue: Influenza Vol. 12, No. 1 January 2006

Research

External links